Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Acute Kidney Failure
8%
Adverse Event
20%
Antibiotics
8%
Antifungal Agent
17%
Apixaban
17%
Atorvastatin
7%
Atrial Fibrillation
17%
Beers Criteria
10%
Carbapenem
8%
Carbapenem Derivative
8%
Cholinergic Receptor Blocking Agent
35%
Cohort Study
5%
Community Pharmacy
25%
COVID-19 Vaccine
8%
Cross Sectional Study
14%
Cross-Sectional Study
100%
Diabetes Mellitus
17%
Diseases
18%
Dosage Form
8%
Drug Interaction
17%
Dyslipidemia
7%
Exposure to Violence
17%
Extended Spectrum Beta Lactamase
8%
FDA Adverse Event Reporting System
25%
Glucagon Like Peptide 1 Receptor Agonist
8%
Hemodialysis
17%
Hospital Mortality
8%
Hospital Pharmacy
8%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
17%
Hypertension
8%
Infection
25%
Low Density Lipoprotein Cholesterol
13%
Lung Disease
8%
Maturity Onset Diabetes of the Young
8%
Multiple Myeloma
17%
Mycosis
17%
Neurologic Disease
17%
Non Prescription Drug
17%
Pharmacovigilance
8%
Prescription Medication
24%
Prevalence
13%
Randomized Clinical Trial
25%
Sodium Glucose Cotransporter 2 Inhibitor
8%
Statin (Protein)
17%
Systemic Mycosis
11%
Tablet
21%
Tacrolimus
8%
Therapeutic Drug Monitoring
17%
Vancomycin
17%
Virus Transmission
8%
Nursing and Health Professions
Accident Prevention
5%
Adverse Drug Reaction
17%
Booster Dose
17%
Chi Square Test
6%
Cholinergic Receptor Blocking Agent
19%
Cigarette Filter
5%
Clinical Outcome
9%
Confidence Interval
6%
COVID-19
17%
Cross-Sectional Study
86%
Cross-Sectional Survey
6%
Deprescribing
25%
Drug Dosage Form
5%
Drug Use
17%
Dyspnea
5%
Exposure to Violence
5%
Gerontology
10%
Health Belief Model
17%
Health Care Personnel
9%
Household
17%
Logistic Regression Analysis
17%
Multiple Linear Regression Analysis
17%
Non Prescription Drug
17%
Odds Ratio
11%
Patient with Diabetes
8%
Patient with Hypertension
8%
Pilot Study
9%
Potentially Inappropriate Medication
25%
Power Analysis
5%
Primary Medical Care
17%
Public Health
8%
Safety Procedure
5%
Saudi Arabia
9%
Study Participant
17%
Therapeutic Drug Monitoring
17%
Thorax Pain
11%
Treatment Duration
17%
University Student
17%
Vancomycin
17%
Verbal Hostility
5%
Medicine and Dentistry
Adverse Event
10%
Arm
8%
Booster Dose
17%
COVID-19
17%
Cross Sectional Study
28%
Diseases
8%
FDA Adverse Event Reporting System
17%
Glucagon-Like Peptide-1 Agonist
8%
Health Belief Model
17%
Ixazomib
5%
Maturity Onset Diabetes of the Young
8%
Medication Compliance
8%
Multiple Myeloma
17%
Non Prescription Drug
17%
Parasympatholytic
36%
Primary Health Care
5%
Primary Outcome
5%
Randomized Clinical Trials
17%
Sodium Glucose Cotransporter 2 Inhibitor
8%
Therapeutic Drug Monitoring
17%
University Student
17%
Vancomycin
17%
